Accent Microcell Ltd
Incorporated in 2001, Accent Microcell Ltd manufactures Pharmaceutical Excipients[1]
- Market Cap ₹ 660 Cr.
- Current Price ₹ 275
- High / Low ₹ 324 / 170
- Stock P/E 19.0
- Book Value ₹ 81.2
- Dividend Yield 0.36 %
- ROCE 23.7 %
- ROE 18.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 51.2% CAGR over last 5 years
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 114 | 131 | 133 | 166 | 197 | 246 | 265 | 278 | |
| 108 | 122 | 122 | 153 | 178 | 206 | 223 | 231 | |
| Operating Profit | 6 | 9 | 11 | 13 | 19 | 39 | 42 | 47 |
| OPM % | 5% | 7% | 8% | 8% | 10% | 16% | 16% | 17% |
| 6 | 4 | 2 | 2 | 2 | 3 | 6 | 6 | |
| Interest | 3 | 3 | 3 | 3 | 3 | 1 | 0 | 1 |
| Depreciation | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| Profit before tax | 5 | 6 | 6 | 8 | 15 | 37 | 44 | 48 |
| Tax % | 24% | 31% | 20% | 22% | 17% | 17% | 24% | |
| 4 | 4 | 5 | 6 | 12 | 30 | 33 | 35 | |
| EPS in Rs | 7.39 | 8.53 | 9.80 | 4.01 | 8.26 | 12.57 | 13.78 | 14.45 |
| Dividend Payout % | 0% | 0% | 9% | 18% | 8% | 7% | 6% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 17% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 51% |
| 3 Years: | 78% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 23% |
| Last Year: | 18% |
Balance Sheet
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 13 | 13 | 21 | 21 |
| Reserves | 17 | 21 | 22 | 19 | 37 | 143 | 174 |
| 32 | 30 | 31 | 24 | 23 | 13 | 2 | |
| 20 | 22 | 23 | 38 | 37 | 28 | 32 | |
| Total Liabilities | 73 | 77 | 81 | 95 | 111 | 205 | 228 |
| 30 | 29 | 30 | 30 | 31 | 29 | 48 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 2 | 13 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 43 | 48 | 50 | 64 | 79 | 174 | 168 | |
| Total Assets | 73 | 77 | 81 | 95 | 111 | 205 | 228 |
Cash Flows
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 6 | 5 | 5 | 15 | 8 | 11 | 25 | |
| -4 | -2 | -6 | -4 | -4 | -82 | -9 | |
| -1 | -2 | -2 | -10 | -4 | 72 | -14 | |
| Net Cash Flow | 1 | 1 | -3 | 1 | -1 | 1 | 2 |
Ratios
Figures in Rs. Crores
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 70 | 60 | 35 | 38 | 56 | 80 | 90 |
| Inventory Days | 67 | 78 | 128 | 128 | 128 | 83 | 76 |
| Days Payable | 89 | 80 | 74 | 97 | 106 | 48 | 42 |
| Cash Conversion Cycle | 48 | 58 | 88 | 68 | 79 | 114 | 124 |
| Working Capital Days | 19 | 30 | 37 | 16 | 41 | 79 | 101 |
| ROCE % | 18% | 17% | 19% | 27% | 31% | 24% |
Documents
Announcements
-
Statement of deviation(s) or variation(s) under Reg. 32
16 October 2025 - Statement of deviation/variation for funds raised via IPO/right issue for half-year ended Sep 30, 2025.
-
Copy of Newspaper Publication
15 October 2025 - Unaudited financial results for half year ended 30 Sep 2025 published in newspapers and uploaded; publication date 15 Oct 2025.
-
Outcome of Board Meeting
14 October 2025 - Board approved unaudited standalone results for half-year ended 30 Sep 2025; limited review and IPO/right proceeds deviation statements.
-
Related Party Transactions
4 October 2025 - Accent Microcell: Regulation 23(9) not applicable for H1 ended 30 Sep 2025; no material related-party transactions.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
3 October 2025 - ACCENTMIC: Regulation 27(2) corporate governance report not applicable for quarter ended 30 Sep 2025 due to SME listing.
Annual reports
Concalls
-
Aug 2025TranscriptPPTREC
-
May 2025Transcript PPT REC
-
Jan 2025TranscriptNotesPPTREC
-
Mar 2024TranscriptNotesPPTREC
Business Overview:[1]
AMC is an EXCiPACT, US-DMF, GMP, ISO 9001:2008, HACCP certified manufacturer and exporter of 22 different grades of Microcrystalline Cellulose (MCC). It caters to 10+ sectors and services 200+ customers in India and worldwide.